JP2015513398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513398A5 JP2015513398A5 JP2014558247A JP2014558247A JP2015513398A5 JP 2015513398 A5 JP2015513398 A5 JP 2015513398A5 JP 2014558247 A JP2014558247 A JP 2014558247A JP 2014558247 A JP2014558247 A JP 2014558247A JP 2015513398 A5 JP2015513398 A5 JP 2015513398A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- seq
- gene
- oligonucleotide according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 29
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 229960004562 carboplatin Drugs 0.000 claims 3
- 190000008236 carboplatin Chemical compound 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 229960005420 etoposide Drugs 0.000 claims 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 101150022024 MYCN gene Proteins 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- SUHQNCLNRUAGOO-KQCZLNONSA-N (4s,5r,6r,7s,8r)-4,6,7,8,9-pentahydroxy-5-[(2-hydroxyacetyl)amino]-2-oxononanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](NC(=O)CO)[C@@H](O)CC(=O)C(O)=O SUHQNCLNRUAGOO-KQCZLNONSA-N 0.000 claims 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 claims 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 101150023956 ALK gene Proteins 0.000 claims 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 102000015790 Asparaginase Human genes 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 108091012583 BCL2 Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 101150115284 BIRC5 gene Proteins 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010539 Congenital megacolon Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000004592 Hirschsprung disease Diseases 0.000 claims 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims 1
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 claims 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 claims 1
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 claims 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101150039798 MYC gene Proteins 0.000 claims 1
- 108700012912 MYCN Proteins 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 108091057508 Myc family Proteins 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 101150005816 PLK4 gene Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102100030128 Protein L-Myc Human genes 0.000 claims 1
- 102100034911 Pyruvate kinase PKM Human genes 0.000 claims 1
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003272 asparaginase Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000012191 childhood neoplasm Diseases 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960005304 fludarabine phosphate Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 claims 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims 1
- 201000007211 kidney clear cell sarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 208000022499 mismatch repair cancer syndrome Diseases 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- 229960004432 raltitrexed Drugs 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims 1
- 229960002110 vincristine sulfate Drugs 0.000 claims 1
- 229960004355 vindesine Drugs 0.000 claims 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2012A000275 | 2012-02-24 | ||
| IT000275A ITMI20120275A1 (it) | 2012-02-24 | 2012-02-24 | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
| PCT/IB2013/051410 WO2013124807A2 (en) | 2012-02-24 | 2013-02-21 | Oligonucleotides for modulating gene expression and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237889A Division JP2018078893A (ja) | 2012-02-24 | 2017-12-12 | 遺伝子発現を調節するためのオリゴヌクレオチド及びこれの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513398A JP2015513398A (ja) | 2015-05-14 |
| JP2015513398A5 true JP2015513398A5 (enExample) | 2016-02-04 |
| JP6333739B2 JP6333739B2 (ja) | 2018-05-30 |
Family
ID=45999941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558247A Active JP6333739B2 (ja) | 2012-02-24 | 2013-02-21 | 遺伝子発現を調節するためのオリゴヌクレオチド及びこれの使用 |
| JP2017237889A Pending JP2018078893A (ja) | 2012-02-24 | 2017-12-12 | 遺伝子発現を調節するためのオリゴヌクレオチド及びこれの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237889A Pending JP2018078893A (ja) | 2012-02-24 | 2017-12-12 | 遺伝子発現を調節するためのオリゴヌクレオチド及びこれの使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10023867B2 (enExample) |
| EP (1) | EP2817407B1 (enExample) |
| JP (2) | JP6333739B2 (enExample) |
| KR (1) | KR101992925B1 (enExample) |
| CN (2) | CN104169421A (enExample) |
| AR (1) | AR090129A1 (enExample) |
| AU (2) | AU2013223694B2 (enExample) |
| BR (1) | BR112014020885B1 (enExample) |
| CA (1) | CA2864060C (enExample) |
| CY (1) | CY1120084T1 (enExample) |
| DK (1) | DK2817407T3 (enExample) |
| ES (1) | ES2651147T3 (enExample) |
| HK (1) | HK1201878A1 (enExample) |
| HU (1) | HUE034846T2 (enExample) |
| IN (1) | IN2014MN01493A (enExample) |
| IT (1) | ITMI20120275A1 (enExample) |
| LT (1) | LT2817407T (enExample) |
| MA (1) | MA35935B1 (enExample) |
| NO (1) | NO2817407T3 (enExample) |
| PL (1) | PL2817407T3 (enExample) |
| PT (1) | PT2817407T (enExample) |
| RS (1) | RS56631B1 (enExample) |
| RU (1) | RU2648140C2 (enExample) |
| SG (2) | SG10201606946YA (enExample) |
| SI (1) | SI2817407T1 (enExample) |
| SM (1) | SMT201800042T1 (enExample) |
| TN (1) | TN2014000327A1 (enExample) |
| WO (1) | WO2013124807A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20120275A1 (it) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
| AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| CA2873769A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating hemoglobin gene family expression |
| SG11201407483YA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating smn gene family expression |
| BR112014028634A2 (pt) | 2012-05-16 | 2017-06-27 | Rana Therapeutics Inc | composições e métodos para modulação da expressão de utrn |
| BR112014028644A2 (pt) | 2012-05-16 | 2017-08-15 | Rana Therapeutics Inc | Composições e métodos para modulação da expressão de atp2a2 |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| EP3556402A4 (en) * | 2016-12-13 | 2020-08-05 | AM Sciences Inc | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS B |
| WO2023182812A1 (ko) * | 2022-03-22 | 2023-09-28 | 주식회사 바이오엔 | 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999009045A1 (en) * | 1997-08-20 | 1999-02-25 | Somagenics, Inc. | Antisense and antigene therapeutics with improved binding properties and methods for their use |
| AU2001235019A1 (en) * | 2000-02-14 | 2001-08-27 | Arthur P Bollon | Libraries of optimum subsequence regions of mRNA and genomic DNA for control of gene expression |
| WO2002083186A1 (en) * | 2001-04-13 | 2002-10-24 | The Population Council, Inc. | Nuclear receptor-mediated introduction of a pna into cell nuclei |
| CN1509292A (zh) | 2001-05-17 | 2004-06-30 | AVI������ҩ��˾ | 使用c-myc反义寡聚物治疗癌症的结合的方法 |
| AU2003213203A1 (en) * | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Incorporated | Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways |
| ITMI20030860A1 (it) | 2003-04-29 | 2004-10-30 | Univ Bologna | Metodo per l'inibizione selettiva del gene n-myc |
| WO2005045032A2 (en) * | 2003-10-20 | 2005-05-19 | Sima Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20080152700A1 (en) * | 2004-06-01 | 2008-06-26 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
| GB0415263D0 (en) * | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
| RU2007119313A (ru) * | 2004-10-25 | 2008-11-27 | Новартис АГ (CH) | Полинуклеотиды и полипептиды torc и способы применения |
| WO2007064945A2 (en) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
| US7625874B2 (en) * | 2006-04-11 | 2009-12-01 | The Regents Of The University Of California | Compositions and methods for treating diseases associated with T-box and N-Myc |
| US20080038783A1 (en) * | 2006-06-29 | 2008-02-14 | Applera Corporation | Compositions and Methods Pertaining to Guanylation of PNA Oligomers |
| US20090047295A1 (en) | 2007-07-12 | 2009-02-19 | Berry David A | Methods and Compositions for Reducing Stemness in Oncogenesis |
| WO2009098464A2 (en) * | 2008-02-05 | 2009-08-13 | Antisoma Research Limited | Biological materials and uses thereof |
| KR101866152B1 (ko) * | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
| CN102058535B (zh) * | 2010-12-21 | 2013-05-01 | 中国人民解放军总医院 | 叶酸受体靶向的新型脂质体 |
| ITMI20120275A1 (it) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
-
2012
- 2012-02-24 IT IT000275A patent/ITMI20120275A1/it unknown
-
2013
- 2013-02-21 PT PT137164158T patent/PT2817407T/pt unknown
- 2013-02-21 PL PL13716415T patent/PL2817407T3/pl unknown
- 2013-02-21 CA CA2864060A patent/CA2864060C/en active Active
- 2013-02-21 US US14/379,729 patent/US10023867B2/en active Active
- 2013-02-21 SI SI201330845T patent/SI2817407T1/en unknown
- 2013-02-21 RS RS20171253A patent/RS56631B1/sr unknown
- 2013-02-21 WO PCT/IB2013/051410 patent/WO2013124807A2/en not_active Ceased
- 2013-02-21 HK HK15102407.6A patent/HK1201878A1/xx unknown
- 2013-02-21 EP EP13716415.8A patent/EP2817407B1/en active Active
- 2013-02-21 JP JP2014558247A patent/JP6333739B2/ja active Active
- 2013-02-21 NO NO13716415A patent/NO2817407T3/no unknown
- 2013-02-21 RU RU2014138198A patent/RU2648140C2/ru active
- 2013-02-21 KR KR1020147026837A patent/KR101992925B1/ko active Active
- 2013-02-21 AU AU2013223694A patent/AU2013223694B2/en active Active
- 2013-02-21 DK DK13716415.8T patent/DK2817407T3/en active
- 2013-02-21 BR BR112014020885-9A patent/BR112014020885B1/pt active IP Right Grant
- 2013-02-21 IN IN1493MUN2014 patent/IN2014MN01493A/en unknown
- 2013-02-21 HU HUE13716415A patent/HUE034846T2/en unknown
- 2013-02-21 CN CN201380009360.1A patent/CN104169421A/zh active Pending
- 2013-02-21 SM SM20180042T patent/SMT201800042T1/it unknown
- 2013-02-21 SG SG10201606946YA patent/SG10201606946YA/en unknown
- 2013-02-21 CN CN202210708144.7A patent/CN115216475A/zh active Pending
- 2013-02-21 ES ES13716415.8T patent/ES2651147T3/es active Active
- 2013-02-21 LT LTEP13716415.8T patent/LT2817407T/lt unknown
- 2013-02-21 SG SG11201404852WA patent/SG11201404852WA/en unknown
- 2013-02-22 AR ARP130100546A patent/AR090129A1/es active IP Right Grant
-
2014
- 2014-07-31 TN TNP2014000327A patent/TN2014000327A1/fr unknown
- 2014-09-10 MA MA37342A patent/MA35935B1/fr unknown
-
2017
- 2017-12-05 CY CY20171101270T patent/CY1120084T1/el unknown
- 2017-12-12 JP JP2017237889A patent/JP2018078893A/ja active Pending
-
2018
- 2018-06-15 US US16/009,303 patent/US10752900B2/en active Active
- 2018-12-13 AU AU2018278972A patent/AU2018278972A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015513398A5 (enExample) | ||
| Gryaznov | Oligonucleotide N3′→ P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents | |
| Boer et al. | DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes | |
| SI2817407T1 (en) | Oligonucleotides for modulating gene expression and their use | |
| AU2022202991A1 (en) | Organic compositions to treat KRAS-related diseases | |
| Pasternak et al. | Unlocked nucleic acid–an RNA modification with broad potential | |
| JP2015502365A5 (enExample) | ||
| TWI816066B (zh) | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 | |
| CA2916989A1 (en) | Inhibition of microrna for treatment of sepsis | |
| TW202313977A (zh) | 作為新穎基因靜默技術的短雙股ｄｎａ及其應用 | |
| AU2022299514A1 (en) | Products and compositions | |
| US20150167004A1 (en) | Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases | |
| JP2021112173A (ja) | 腫瘍細胞の生存を低下させるｋｒａｓアンチセンスオリゴヌクレオチド及びその用途 | |
| CN107630015B (zh) | 一种稳定的dna-rna双链结构 | |
| EP4396347B1 (en) | Chimeric complex and therapeutic uses thereof | |
| WO2024228398A1 (ja) | グアニン四重鎖構造を誘導するための核酸剤 | |
| Lesnikowski et al. | An effect of stereochemistry on transport of tetra (thymidine methylphosphonate) across organic liquid barrier | |
| Hess et al. | Antisense Oligodeoxyribonucleotides (AS-ODNs) for Cancer Gene Therapy: A Clinical Perspective |